Andrew Foxley

Andrew Foxley is a one of the Vice President Franchise Heads in Late Development Oncology R&D at AstraZeneca. In his role he leads the cross-functional R&D Franchise for development and launch of a number of late-stage oncology molecules. He joined AstraZeneca Clinical Operations in 2003 and has since held positions in both clinical operations and strategic drug development with increasing levels of responsibility including development and delivery of a wide range of international drug development programmes.  Before joining AstraZeneca, he was an Executive Director and Company Board Member at Nottingham Clinical Research Limited, a contract research organisation specialising in the design and delivery of large-scale cardiovascular studies, where he played a leading role in developing the enterprise from a university spin-off company. Outside AstraZeneca, he has been Chair of the New Medicines and Data Strategic Leadership Group at the Association of the British Pharmaceutical Industry and Co-chair of the UK Clinical Pharmacology Skills Alliance and chairs the UK Clinical Pharmacology Trailblazer Apprenticeship Group.  Andrew is an active visiting mentor at the Cambridge University Judge Business School and Guest Lecturer for the MPhil in Molecular Mechanisms of Human Disease at the University of Cambridge.